Macías-García F, Domínguez-Muñoz JE. Update on management of Barrett's esophagus. World J Gastrointest Pharmacol Ther 2016; 7(2): 227-234 [PMID: 27158538 DOI: 10.4292/wjgpt.v7.i2.227]
Corresponding Author of This Article
Fernando Macías-García, MD, Department of Gastroenterology and Hepatology, University Hospital of Santiago de Compostela, Choupana s/n, 15706 Santiago de Compostela, Spain. fmacgar@yahoo.es
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Pharmacol Ther. May 6, 2016; 7(2): 227-234 Published online May 6, 2016. doi: 10.4292/wjgpt.v7.i2.227
Update on management of Barrett's esophagus
Fernando Macías-García, J Enrique Domínguez-Muñoz
Fernando Macías-García, J Enrique Domínguez-Muñoz, Department of Gastroenterology and Hepatology, University Hospital of Santiago de Compostela, 15706 Santiago de Compostela, Spain
Fernando Macías-García, J Enrique Domínguez-Muñoz, Foundation for Research in Digestive Diseases (FIENAD), University Hospital of Santiago de Compostela, 15706 Santiago de Compostela, Spain
Author contributions: Macías-García F wrote the paper; Domínguez-Muñoz JE supervision and final approval of the article.
Conflict-of-interest statement: Authors declare no conflict of interests for this article.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Fernando Macías-García, MD, Department of Gastroenterology and Hepatology, University Hospital of Santiago de Compostela, Choupana s/n, 15706 Santiago de Compostela, Spain. fmacgar@yahoo.es
Telephone: +34-98-1951364 Fax: +34-98-1951365
Received: April 25, 2015 Peer-review started: April 27, 2015 First decision: September 8, 2015 Revised: December 15, 2015 Accepted: February 14, 2016 Article in press: February 16, 2016 Published online: May 6, 2016 Processing time: 361 Days and 5.2 Hours
Abstract
Barrett's esophagus (BE) is a common condition that develops as a consequence of gastroesophageal reflux disease. The significance of Barrett's metaplasia is that predisposes to cancer development. This article provides a current evidence-based review for the management of BE and related early neoplasia. Controversial issues that impact the management of patients with BE, including definition, screening, clinical aspects, diagnosis, surveillance, and management of dysplasia and early cancer have been assessed.
Core tip: Barrett’s esophagus (BE) is a common condition that predisposes to cancer development. This article provides a current evidence-based review for controversial issues that impact the management of patients with BE, including clinical aspects, diagnosis, surveillance, and management of dysplasia and early cancer.
